Drawing on years of experience studying non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD), SMC has created the world’s first preclinical model with a type 2 diabetic ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

Nonalcoholic fatty liver disease (NAFLD) and its more severe form NASH are common liver diseases in industrialized countries. Diabetes, obesity, the metabolic syndrome and NAFLD all share common ...

Non-Alcoholic Fatty Liver Disease (NAFLD) is emerging as a significant global health concern, driven by increasing rates of obesity, diabetes and sedentary lifestyles. NAFLD includes a spectrum of ...

According to him, NAFLD, if severe and progressing, can lead to an irreversible condition—liver cirrhosis, with non-alcoholic ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...